Envista (NVST) Competitors $17.78 +0.08 (+0.45%) As of 05/20/2025 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NVST vs. SNN, PEN, STVN, GKOS, NARI, INSP, IRTC, BLCO, TMDX, and SLNOShould you be buying Envista stock or one of its competitors? The main competitors of Envista include Smith & Nephew (SNN), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Inari Medical (NARI), Inspire Medical Systems (INSP), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), TransMedics Group (TMDX), and Soleno Therapeutics (SLNO). These companies are all part of the "medical equipment" industry. Envista vs. Smith & Nephew Penumbra Stevanato Group Glaukos Inari Medical Inspire Medical Systems iRhythm Technologies Bausch + Lomb TransMedics Group Soleno Therapeutics Smith & Nephew (NYSE:SNN) and Envista (NYSE:NVST) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Does the MarketBeat Community prefer SNN or NVST? Smith & Nephew received 414 more outperform votes than Envista when rated by MarketBeat users. Likewise, 54.10% of users gave Smith & Nephew an outperform vote while only 32.71% of users gave Envista an outperform vote. CompanyUnderperformOutperformSmith & NephewOutperform Votes44954.10% Underperform Votes38145.90% EnvistaOutperform Votes3532.71% Underperform Votes7267.29% Is SNN or NVST more profitable? Smith & Nephew has a net margin of 0.00% compared to Envista's net margin of -44.56%. Envista's return on equity of 3.86% beat Smith & Nephew's return on equity.Company Net Margins Return on Equity Return on Assets Smith & NephewN/A N/A N/A Envista -44.56%3.86%2.21% Do analysts recommend SNN or NVST? Smith & Nephew currently has a consensus price target of $28.00, suggesting a potential downside of 4.70%. Envista has a consensus price target of $20.08, suggesting a potential upside of 12.92%. Given Envista's stronger consensus rating and higher possible upside, analysts clearly believe Envista is more favorable than Smith & Nephew.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Smith & Nephew 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Envista 1 Sell rating(s) 10 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.14 Does the media favor SNN or NVST? In the previous week, Envista had 2 more articles in the media than Smith & Nephew. MarketBeat recorded 8 mentions for Envista and 6 mentions for Smith & Nephew. Smith & Nephew's average media sentiment score of 1.71 beat Envista's score of 1.13 indicating that Smith & Nephew is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Envista 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of SNN or NVST? 25.6% of Smith & Nephew shares are held by institutional investors. 1.0% of Smith & Nephew shares are held by insiders. Comparatively, 1.3% of Envista shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, SNN or NVST? Smith & Nephew has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Envista has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Which has higher valuation and earnings, SNN or NVST? Smith & Nephew has higher revenue and earnings than Envista. Envista is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSmith & Nephew$5.81B2.21$263M$2.1613.60Envista$2.50B1.20-$1.12B-$6.53-2.72 SummarySmith & Nephew beats Envista on 10 of the 18 factors compared between the two stocks. Get Envista News Delivered to You Automatically Sign up to receive the latest news and ratings for NVST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVST vs. The Competition Export to ExcelMetricEnvistaDental equipment & supplies IndustryMedical SectorNYSE ExchangeMarket Cap$3.01B$3.87B$5.42B$19.70BDividend YieldN/A2.06%5.22%3.84%P/E Ratio-2.7439.4326.8335.12Price / Sales1.201.39393.8634.12Price / Cash12.916.5738.2517.51Price / Book1.040.686.874.78Net Income-$1.12B-$146.24M$3.22B$1.02B7 Day Performance-4.92%3.10%5.65%0.90%1 Month Performance17.07%17.22%13.54%11.10%1 Year Performance-2.68%-20.48%18.16%5.28% Envista Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVSTEnvista4.0514 of 5 stars$17.78+0.5%$20.08+12.9%-2.7%$3.01B$2.50B-2.7412,700Positive NewsGap UpSNNSmith & Nephew2.266 of 5 stars$28.43+0.3%$28.00-1.5%+12.9%$12.45B$5.81B13.1620,100News CoveragePENPenumbra4.4338 of 5 stars$296.98-0.1%$302.40+1.8%+39.5%$11.50B$1.24B873.473,900Positive NewsSTVNStevanato Group1.2604 of 5 stars€23.64-1.5%N/A+21.2%$7.16B$1.10B50.304,650Positive NewsGKOSGlaukos4.6725 of 5 stars$94.57+5.1%$134.67+42.4%-10.7%$5.40B$404.52M-32.95780News CoveragePositive NewsNARIInari Medical0.472 of 5 stars$79.97flat$69.22-13.4%N/A$4.68B$493.63M-59.24800News CoverageINSPInspire Medical Systems4.7118 of 5 stars$156.54+3.5%$211.91+35.4%-3.4%$4.62B$840.11M90.49760Positive NewsGap UpIRTCiRhythm Technologies1.3027 of 5 stars$137.80+0.1%$128.55-6.7%+52.5%$4.40B$618.59M-37.861,790Positive NewsBLCOBausch + Lomb4.3015 of 5 stars$11.91+5.6%$15.50+30.2%-19.2%$4.21B$4.83B-13.0812,500Gap UpTMDXTransMedics Group1.4365 of 5 stars$118.73+6.5%$126.70+6.7%-10.0%$4.02B$488.23M126.31210Positive NewsSLNOSoleno Therapeutics4.8661 of 5 stars$76.70-0.1%$106.78+39.2%+59.6%$3.87BN/A-23.1030News CoveragePositive News Related Companies and Tools Related Companies Smith & Nephew Alternatives Penumbra Alternatives Stevanato Group Alternatives Glaukos Alternatives Inari Medical Alternatives Inspire Medical Systems Alternatives iRhythm Technologies Alternatives Bausch + Lomb Alternatives TransMedics Group Alternatives Soleno Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NVST) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Envista Holdings Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Envista With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.